Transgene (FRA:TGNA) FFO


FRA:TGNA Transgene SA FRA:TGNA
45 GF Score
Price €0.70
GF Value €0.51
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene FFO?

FFO (Funds from operations) only applies to REITs.

FRA:TGNA
45GF Score
Transgene SA FRA:TGNA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Transgene (FRA:TGNA) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.70 is trading 38% above its estimated GF Value™ of €0.51. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for FRA:TGNA:

  • FFO:
  • GF Value™: €0.51 vs. price of €0.70 (38% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the FRA:TGNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Other Exchanges TRGNF:USA0OCQ:UKTNG:France
Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
45GF Score

Get the complete analysis for FRA:TGNA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.70
Price
€0.51
GF Value